Probiotics, their Health Benefits and Applications for Development of Human Health: A Review by Sanap, Deepali Sanjay et al.
Sanap et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):631-640 
ISSN: 2250-1177                                                                                  [631]                                                                                 CODEN (USA): JDDTAO 
Available online on 15.08.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                                Review Article 
Probiotics, their Health Benefits and Applications for Development of 
Human Health: A Review 
Sanap Deepali , Garje Mahesh  and Godge Ganesh * 
Department of Pharmaceutics, Dr.V.V.P.Foundation’s College of Pharmacy, Ahemednagar-414 111, Maharashtra, India 
 
ABSTRACT 
Gastrointestinal microbial flora plays a major role in health of host. The person with the healthy digestive system is the indication of proper 
health. Probiotics bacteria are live nonpathogenic microorganism which has beneficial effects on host gastrointestinal tract which is mentioned 
in articles viz. Recent Advances in Pharmaceutical Approaches to Colon Specific Drug Delivery. Optimum population of probiotics bacteria are 
essential for the maintenance and effective functioning of the digestive system. Hence probiotics are the good therapeutic agents for the various 
abnormal conditions of gastrointestinal tract such as inflammatory bowel disease, chrohn’s disease, colon cancer etc. Probiotic micro biota also 
fights against pathogenic infections of GIT such as H. pylori infection by production of some antimicrobial chemical secretions such as 
bacteriocin. Recent studies and innovations and studies found that the probiotic bacteria are beneficial in the prevention and curative 
treatment of various disease and disorders like colorectal cancer, infection of urinary tract (UTI), allergic condition, card iovascular disorders 
and depressive disorders. Probiotics are administered as nutraceutical products in the form of both conventional pharmaceutical dosage forms 
and traditional non-conventional food products, inclusion complexes with cyclodextrins effectively, sustained release tablets by solid 
dispersion technology etc. Probiotics are significantly gaining popularity due their wide application and safety. This paper presents the 
comprehensive review on the probiotics profile along with its some therapeutic applications, delivery approaches and current aspects.   
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INTRODUCTION: 
Probiotics are living or viable bacteria which act as 
supplementary microorganisms that exhibit beneficial 
health effect on the host’s health by enhancing its 
gastrointestinal microbial balance. Healthy life is a dream 
of every person and healthy digestive system is basically 
indication of good health. [1, 2, 3]The Food and Agriculture 
Organization (FAO) and the World Health Organization 
(WHO) have defined probiotics as, “Live microorganisms, 
which when administered in adequate amounts confer a 
health benefits on the host.”[4, 5, 6] 
The term ‘Probiotics’ was first applied by Stillwel and Lilly 
in 1965 to the substance which is produced by one 
microorganism and that promote the growth of another. 
Later on 1974, Porker proposed a definition of probiotics 
as, “organisms and the substances, which contribute to 
intestinal microbial balance.”[7] Each and every 
microorganism cannot be considered as a probiotics. There 
are certain criteria’s for considering microbial strain as a 
probiotic. According to WHO/ FAO guidelines regarding to 
probiotics, the manufacturer who performs the 
manufacturing of probiotics, should register their strain 
with on International Depository. [8] 
Effectiveness and activity of probiotics can be enhanced by 
substances called ‘Prebiotics’.  These prebiotics act as 
supplement to the probiotics bacteria. The combination of 
prebiotics along with probiotics is termed as ‘symbiotics’. 
The useful and promising strains of probiotics include 
various members of genera Bifidobacterium, Lactobacillus 
and Enterococcus. The representatives of above genera are 
Lactobacillus acidophilus, L. johnsonni, L. casei, Lactobacillus 
gasseri, L. rhamnosus, L. plantarum. The species of 
Bifidobacterium includes the Bifidobacterium longum, 
Bifidobacterium breve, Bifidobacterium bifidum, and 
Bifidobacterium infantis. Enterococcus are E.faecalis and E. 
faecium. [9, 10, 11, 12] 
Probiotics provide variety of benefits. It provide effect on 
immunological functions, aid in digestion, protect GIT from 
the infectious bacteria such as H. pylori, E. coli. Probiotics 
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are also used to improvement of lactose intolerance, to 
lower the body cholesterol level, to treat chronic disease, 
ulcerative colitis, IBS and in antibiotics associated diarrhea. 
Probiotics also used as a medium or carrier of drug 
delivery to the GI tract. Probiotics are delivered in various 
forms such as food product, deep-freeze form, dairy 
products, meat etc. [13] 
 
 
COMPOSITION OF GUT FLORA:-[13] 
 
Fig. 1 Detail Composition of Gut Flora 
MECHANISM OF ACTION OF PROBIOTICS:-  
Probiotics act by several mechanisms, such as maintenance 
and enhancement of epithelial barrier, improved adhesion to 
intestinal mucosa and simultaneous inhibition of adhesion of 
pathogen, competitive exclusion of pathogenic microbes, 
generation of anti-microbial substances and 
immunomodulation action. [14, 15] 
Intestinal barrier is major defense mechanism which 
maintains intestinal integrity and function. Intestinal barrier 
composed of layer of mucous, peptides having activity 
against microbes, IgA and epithelial junction adhesion 
complex. Probiotic bacteria have effect on various 
component of epithelial barrier by more production of 
intestine. [16, 17] 
Probiotics act by prevention of the colonization of various 
pathogenic bacteria in gastrointestinal tract (GIT). Probiotics 
also act by preventing the binding of pathogenic microbes to 
enterocyte by producing inhibitory components such as 
Lactic acid, bacteriocin, and toxic metabolites of oxygen. The 
attachment of probiotics to receptor initiates the signal 
which results in cytokines production. The Butyric acid 
synthesis causes increased enterocytes turnover and 
neutralization of dietary carcinogen. Specific serum IgA 
production results in enhanced immune response [9, 18, 19, 20, 
21] 
By these several mechanisms the probiotics keeps the 
gastrointestinal tract healthy. 
IDEAL PROPERTIES OF PROBIOTICS:- 
1. Resistant to digestion. 
2. Highly adherent to the cell of intestinal wall. 
3. Stability in gastric acid, bile, oxygen and various 
enzymes. 
4. Ability to produce anti- microbial agents for intestinal 
tract protection. 
5. They should not be pathogenic to body and should be 
safe. 
6. Should have ability to maintain sufficient normal 
balanced flora. 
COMMERCIAL PROBIOTIC MICROORGANISMS:-[7, 9] 
Some commercially marketed formulations of probiotics are 
given below.
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Table .1 Some Commercially Marketed Formulations of Probiotics 
 
APPLICATIONS/ THERAPEUTIC USES:- 
Many diseases and abnormal physiological conditions are 
treated with use of probiotics. On the basis of animal studies, 
preliminary human models study, uncontrolled studies such 
numerous studies provide encouraging evidence that 
specific strains of probiotics are beneficial in the preventing 
and treating the various diseases and conditions. The 
probiotics have various potential benefits including 
improved nutrition, growth and prevention & treatment of 
various gastrointestinal disorders. The various therapeutic 
uses of probiotics are briefly described as follows- [6, 22, 21] 
1. Cancer  
Currently in the world cancer is one of the major cause of 
death of humans. Among them near about 75% of cancer 
suffered patients dies which are related to their diet and 
lifestyle, where about 50% of these deaths are associated 
with diets. (World Cancer Research Fund, 1997). Colon 
Cancer or colorectal cancer is the most prevalent form of 
cancer, which are specially   associated with human habits of 
diet. According to certain animal studies and some in vitro 
studies shows that the intestinal or gut microbial flora may 
exhibit anticancer activity. But fact is that study is limited 
only up to in vitro testing. Animal and clinical trials are still 
not performed. They decreases risk associated with the diet. 
So, probiotics may serve as a beneficial role in the colon 
cancer and superficial bladder cancer. [7, 23] The pathological 
imbalance in the gastrointestinal microbial community is 
observed in the affected subjects as compared to the normal 
subjects. In the case of colorectal cancer, many potential 
pathogen such as Pseudomonas, Acinetobacter and 
Helicobacter and decreased level of the beneficial bacteria, 
like butyrate producing bacteria are observed. Due to this 
imbalance between the pathogenic bacteria and beneficial 
bacteria, this condition promotes implementation and 
tumorigenesis in colon which directly leads to colorectal 
cancer. [24] 
There are many in vitro experiments are undergoing to 
demonstrate the cytotoxic effect of some lactic acid bacteria 
(LAB) strains in cancerous cells. The probiotic may be useful 
in malignant tumor but not in benign tumour. They act by 
various mechanisms. The probiotics get agglomerated in 
malignant tumour cells and this agglomeration is less in 
organ such as spleen and liver. [13] Probiotic act by increased 
synthesis of the cytokines such as Interleukins (IL-2 and IL-
12), some antioxidants (SOD, GSH, CAT) and Anti-angiogenic 
factors. They also reduce damage to DNA, many carcinogenic 
enzymes, proteins which are specific to carcinogenicity and 
size of tumour. Various metabolites of probiotic bacteria 
have suppression action colon cancer development. It 
includes SCFAS, Acetate, propionates, butyrates. From the 
experimental study it is found that butyrate exhibit anti-
tumour effect by inducing apoptosis, preventing 
proliferation, certain changes in expression pattern of gene 
and modulation of cytokines. In vitro study of Lactobacillus 
fermentum NCIMB-5221 and NCIMB-8829 showed action on 
colorectal malignant cells by promoting normal epithelial 
colon cell growth due to the production of SCFA’s i.e. ferulic 
acid. Other species of probiotic strains like Lactobacillus 
acidophilus LA102 and L. caseiLC232 showed a significant 
cytotoxic activity and proliferative activity against 2 
colorectal cell lines. So the dietary control may play major 
role in controlling and management of cancer. Probiotic 
delivery which modulate the gastrointestinal microbial 
Sr.no. Product name Comment Culture of probiotics used 
1 Flora Grow 
(Arise & Shine) 
Generate pH between 6.5 and 7. Because essential 
bacteria in GIT tract start to die off. 
Bifidobacterium infantis,  
Bifidobacterium longum, 
Bifidobacterium bifidum 
2 Bioflorin 
(CerbiosPharma) 
Used for the prophylaxis and treatment of intestinal 
diseases 
Enterococcus LAB SF 68 
3 Subalin  Recombinant Bacillus subtilis 
4 SWELTY® Gastro Protect 
(Nestle) 
It protect the stomach from H. pylori infection and 
controls stomach discomfort 
Lactobacillus johnsonii La 1 
5 Kyo-Dophilus tablets 
( Wakanaga Probiotics) 
This is a stable formulation. Refrigeration is not 
essential. It is chewable, sugar free , tasty and is 
completely vegetarian   
Lactobacillus acidophilus 
6 Align (Procter y Gamble) Available as capsule form and daily single dose keep 
digestive system healthy with healthy bacteria. 
Bifidobacterium infantis 35624 
7. Bifa 15  
(Eden Foods) 
The bacterial strain is encapsulated so as to bypass 
the stomach acidic environment and reaches to the 
colon 
Bifidobacterium longum 
 
8 URO VAXAM ® 
(Apsen) 
Used in immunotherapy and protect lower urinary 
tract 
Escherchia coli 
 
 
9. Kyo-Dophilus capsules  Each capsule contains about 1.5 billion live bacterial 
strain cells. 
Lactobacillus acidophilus,  
Bifidobacterium bifidum, 
Bifidobacterium longum 
10 Activia® Yogurt 
(Danone) 
It helps in regulation of digestion function of 
digestive system 
L. bulgaricus, 
S. thermophilus 
 
11 Mutaflor 
(Ardeypharm) 
It is beneficial in IBS and functional bowel disease. Escherschia coli nissle 1917 
 
12. TH1 Probiotics 
(Jarrow formulas) 
It contain heat treated strains so they are safe in case 
of persons having leaky gut and is severely immune 
compromised. 
Bifidobacterium longum, 
Saccharomyces boulardi, 
Lactobacillus casei, 
Lactobacillus plantarum. 
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community is become great approach and have good 
potential to prophylaxis and treatment of cancer. [25, 26, 27, 28]  
         Strains used:-L. acidophilus, L. caseishirota strains and 
Lactobacillus GG 
2. Gastrointestinal application[29] 
Probiotics are very beneficial in preventing and treating of 
GIT related diseases and disorders. There are some 
probiotics which prevents diverse intestinal diarrhoea 
inducing disorders like lactose indigestion. Some are 
responsible for the treatment and prophylaxis of 
gastrointestinal and urogenital infections. Banerjee I, Pal K 
and Babu N et.al. Formulated emulsion gel as carrier based 
probiotics formulation for gastrointestinal conditions like 
diarrhea, chrohn’s disease and ulcerative colitis. [30] 
Probiotics are able to inhibit the mutagenicity of 
gastrointestinal contents and reduces the incidences of 
gastrointestinal tumors. Some useful traits of the probiotics 
responsible for the illustration of bile tolerance, acid 
resistance and attachment to the epithelial tissue of host to 
show the action as antagonist for pathogenic 
microorganisms. [4] Probiotics species like L. plantanum 
generally used to cure flatulence and abdominal pain; L. GG, 
L. reutri and S. boulardii generally cures overall conditions of 
GI tract. GI disorders like diarrhea, paining, bloating can be 
treated with S. boulardii. [31] Mateescu MA, Calinescu C 
developed chitosan self-stabilized matrix based colon 
targeted probiotics formulation. [32] 
3. Antipathogenic activity[33,34] 
One of the important and useful effect of probiotics is 
antipathogenicity. Probiotics are used to inhibition of the 
growth of pathogenic bacteria by the production of SCFA’s 
(short chain fatty acids) which maintains the pH of the 
colonic lumen at the appropriate conditions. As the probiotic 
bacteria are non-pathogenic bacteria they have ability to 
inhibit pathogenic bacteria and protect the body. Some of 
the probiotics produces compounds like bacteriocin, 
ethanol, organic acid, diacetyl, acetaldehydes, hydrogen 
peroxides and peptides which have anti-pathogenic action. 
Anti-pathogenic compounds like bacteriocin and peptides 
increases the membrane permeability of target cells which 
causes depolarization of cell membrane potential and which 
finally leads cell death. Some of the probiotics activates anti-
pathogenic defense pathways in the host. [35] 
4. Care of UTI[15, 35, 36] 
Infection of urinary tract by various pathogens and bacteria 
is termed as ‘Urinary Tract Infection’ (UTI). It is most 
commonly prevailing problem often seen in young as well as 
elder women’s. Bacterial infection is the major cause of UTI. 
Many UTI occurs due to the imbalance vaginal microbial 
flora. The affected site can be either lower urinary tract or 
upper urinary tract. Upper urinary tract involves the ureters 
and kidneys. If infection is limited to the urethra and urinary 
bladder then it is called lower urinary tract infection. When 
bacteria enter into the urinary tract and start to grow it lead 
the infection at that site. So lactic acid producing bacteria are 
suggested for UTI from many years. In 1973, lactobacilli 
were observed in vagina of women having no history of 
urinary tract infection. Many of the medicines fail to cure the 
UTI’s because of resistance to the medicines. So to cure the 
UTI’s there are 50 probiotics species which normalize the 
microbial flora of vagina. Out of 50 species, Lactobacillus 
species highly influences the microbial environment of 
vagina. Lactobacillus species like Lactobacillus brevis, L. 
casei, L. vaginalis, L. salivarius, L. reuteri, L. delbrueckii and, L. 
rhamnosus mainly effects on vagina in the conditions of the 
bacterial vaginois (BV) and infection of urinary tract (UTI). 
Different UTI’s can be cured by using above species through 
the supplement of probiotics. The different species can be 
administered through vaginal suppositories to cure the 
urinary tract infections with minimum side effects. Despite 
there are sufficient clinical evidences demonstrating the 
effective use of probiotics on urogenital and urinary tract 
health still there is no sufficient data available to the regular 
use of such microbiota in urological disorders. Because very 
less number of trails performed on minimum human 
subjects.  
5. Probiotics against diabetes 
Generally, probiotics used to enhance the microbial flora in 
GIT of human body to neutralize any disorder.  Probiotics 
are given with supplementation for proper treatment of any 
disease or disorder Type-2 diabetes shows significant 
reduction in the gram +ve firmicutes species. Type-2 
diabetes can be treated with the help of probiotics by 
modulation of gut hormones like gastric inhibitory 
polypeptide along with glucagon like peptides. Hormone 
control glucose homeostasis which in turn neutralizes the 
type-2 diabetes produced due to peripheral insulin 
resistance. Failure of β- cells in producing insulin can also be 
treated with the help of probiotics. New probiotics like 
arabinoxylan and arabinoxylan oligosaccharides resists 
metabolic disorders by reducing the growth of adipocyte 
tissues. Prakash S & Lomis L studied the combination of 
three different metabolically active probiotic strains, Lf5221, 
Lp8826 and Bi702255 and they concluded that this 
combination effectively recovered all aspects of diet induced 
diabetes as well  as obesity. If we added some prebiotics 
along with probiotics we get more prominent results. [14, 33, 
37] 
6. Probiotics against obesity 
Obesity can be characterized by some factors like increase in 
energy availability, abnormality in energy uptake and 
expenditure, sedentariness etc. Some probiotics have 
physiological function that regulates body weight. Probiotics 
strains like Lactobacillus gasseri BNR17 inhibit the growth of 
an adipocyte tissue which contains leptin and adiponectin 
responsible for obesity. Other strains of probiotics viz; 
Lactobacillus acidophilus, Lactobacillus casei, and 
Bifidobacterium longum possess hypocholesterolemic 
effects. Generally probiotics facilitates weight loss by 
thermogenic as well aslipolytic response via stimulation of 
adrenergic nervous system. [35, 37, 38]  Probiotics species like 
Lactabacillus reuteri CRL1098 decreases cholesterol level in 
hypercholesterolemic conditions. It also reduces level of 
triglycerides and the ratio of high density lipoprotein (HDL) 
to low density lipoprotein (LDL) without any translocation 
of microbial flora. [9] 
7. Probiotics against inflammatory diseases 
Inflammatory diseases of GIT like Chrohn’s disease (CD) and 
ulcerative colitis (UC) can also be treated with the help of 
probiotics. Generally, CD may causes inflammation of any 
part of GIT or may spread to the whole GIT. Both aerobic and 
anaerobic bacteria contribute to the inflammatory action on 
GIT. While ulcerative colitis (UC) causes inflammation only 
to the large bowel. Inflammation may cause to the mucosal, 
sub mucosal or serosal level. Inflammation can caused with 
the supplements of probiotics, prebiotics and synbiotics. 
Combination of Chrohn’s disease with the ulcerative colitis 
known as the inflammatory bowel disease. The certain genes 
like mutant of the NOD2/CARD15 on chromosome 16 are 
associated with the chrohn’s disease. IBD is characterized 
with abnormal production of the short chain fatty acid 
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(SCFA’s). SCFA’s are important to maintain colonic 
homeostasis and have an anti-inflammatory effect. But the 
abnormality in SCFA’s produces IBD. Indigestible 
carbohydrates and fiber as a single component or in 
combination with probiotic supplement normalize the 
production of SCFA’s. Generally strains of Lactobacillus, 
Bifidobacillus, E. coli and Enterobacter are widely used to 
treat inflammation. Some genetically engineered probiotics 
traits produces immune-modulators likeinterleukin-10, 
trefoil factors, which help to improve immune system of 
host. [39, 40, 41] 
8. Probiotics against allergy 
Recent advanced study on probiotics showed an anti-allergy 
effect of probiotics. In vitro study of strains of Lactobacillus 
plantarum L67 & 06CC2 showed significant results to 
alleviate allergy symptoms. Allergy associated with disease 
and disorders treated using Lactobacillus plantarum L67 
which produces interleukin-12 & interferon-γ in host 
system. L. plantarum 06CC2 alleviates all the symptoms of 
allergy & decreases level of immunoglobulin E and 
histamine. In case of L. plantarum 06CC2 showed that 
increase in secretion of interferon-γ & interleukin-4 in the 
spleen cells of mice and they are responsible for the 
prevention of allergic symptoms. [9, 30, 42] 
9. Probiotics and angiogenesis 
Angiogenesis is one of the important process or 
phenomenon in which new vessel generated from pre-
existing blood vessels. It is also useful in wound healing 
process. Improper angiogenesis leads to the chronic 
disorder such as cancer, IBD with CD and UC, diabetic 
retinopathy. A probiotics are found to be beneficial in the 
heart conditions like coronary heart disease, and notably act 
on risk factors associated with heart diseases such as 
cholesterol and TAG. A probiotic strain S. boulardii protect 
host body against intestinal injury &inflammation. S. 
boulardii is a non- pathogenic yeast species. Molecular 
mechanism behind the action of probioticsnot been clear. 
But it may be act by decrease in visceral hypersensitivity, 
altering inflammatory cytokine profiles, increase in 
epithelial barrier function, down regulation of pro-
inflammatory cascade etc. [35, 43, 44] 
10. Probiotics and CNS 
In recent years, some studies carried out to see the effect of 
gut microbiota on brain and CNS. Many clinical trials showed 
positive results for effect of microbial flora in gut on the 
brain and CNS. Daily dose of L. plantarum WCFS1 showed 
improvement in the children having autism. Lactobacillus 
helveticus R0052 & R0175 lowers down the psychological 
distress. Anxiety symptoms in chronic fatigue syndrome can 
be reduced by L. casei.  Probiotic strain. L. rhamnosus also 
used to prevent symptoms in autism spectrum & attention 
deficit/ hyperactivity disorder. Some gut bacteria produces 
neuroactive compounds which are similar to the compounds 
present in host brain. Study on L. brewis DPC6108 & 
Bifidobacterium dentium shown that they produce a brain 
neurotransmitter γ-amino butyric acid (GABA) in large 
quantity. GABA helps to suppress the anxiety and 
depression. Combinations of different strains of probiotics 
can be able to recover the cognitive reactivity of victim to 
the sad mood. CNS and brain disorders can be cured with the 
help of species viz; B.lactis W, L. acidophilus W37, 
lactococcuslactis W19 & W58, L. salivarius W2, L. casei W5, 
Bifidobacterium bifidum, L. brevis W etc. Administration of L. 
acidophilus through oral route regulates mood of people 
towards rewards and their addictive behavior. [35, 45, 46] 
11. Probiotics for immunologic enhancement 
The person having strong immune system is basic indication 
of the healthier person. There are different component 
which modulate host immune system. Interleukins, 
prostaglandin E production, TNF, gamma interferon, serum 
protein, albumin, and globulin are some intrinsic component 
of body that have effect on host immunity. There are several 
studies reported that probiotics like lactobacilli can be used 
to enhance the immune sytem of host. They have ability to 
modulate the immunological response. The probiotics like 
Lactobacillus rhamnosus GG causes the proliferation of 
murine T and B lymphocytes and shows the 
immunomodulatory effects.  Their actions are specific dose 
dependant and duration dependant. Bifidobacterium breve 
YIT4064. When administered orally it causes the activation 
of human immune system by increasing production of anti-
rotavirus IgA or production of anti-influenza virus IgG. 
Hence Bifidobacterium breve YIT4064 protect the host 
against influenza virus infection and rotavirus infection. 
Some probiotic bacteria act on proliferation of cell, 
production of nitric acid and cytokine. Such probiotics are 
heat killed strains, cytoplasmic extracts including cell wall of 
Lactobacillus acidophilus, L.gasseri, Lactobacillus bulgaricus, 
Lactobacillus reuteri, Lactobacillus casei, Lactobacillus 
helveticus and Streptococcus thermophilus. Cell wall as well 
as cytoplamic fraction of extract of probiotics produces 
essential amount of certain immunological factors such as 
IL-6 (interleukin-6), tumournacrosis factor-α and nitric 
oxide (NO). From these studies it is observed that lactic acid 
bacteria have power to stimulate the macrophages & may 
stimulate other immune cells which produces the nitric 
oxide (NO) and cytokines. Cytoplasm and also cell wall of 
probiotic bacteria have such capabilities. There are various 
different mechanism and actions are observed on different 
animals such as rats and mice. They stimulate helper T cells 
(Type 1), decreases the immunoglobulin E (IgE) production 
and decreases the chances of tumors. [24, 62] 
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Fig. 2. Immunomodulation Mechanisms of Probiotics 
 
12. Probiotic and Respiratory diseases.[7] 
The probiotics used as preventive agent in certain 
respiratory tract diseases. Due to the capability of probiotics 
to exhibit different actions such as immunomodulation, 
production of substances having antimicrobial activity, 
probiotics directly shows their action on the pathogenic 
microorganism. Hence different strains of bacteria can be 
used in respiratory tract disorders. The respiratory tract 
disorders include pharyngitis, bronchitis, rhino sinusitis, 
sinusitis, otitis etc. The various species are employed either 
single or in combination with other. Administration of the 
Lactobacillus rhamnosus GG in patients having cystic fibrosis 
decreases exasperated episodes of pneumonia significantly. 
Probiotic bacteria such as Lactobacillus rhamnosus and L. 
plantarum are used to prevent nosocomial pneumonia. In the 
nosocomial pneumonia pathogenic bacteria Pseudomonas 
auroginosa are colonized in respiratory tract. Other species 
used to reduce episodes of respiratory disease are 
lactobacillus casei, Lactobacillus plantarum, lactobacillus 
fermentum VRI-003, Bifidobacterium longum SP 07/3, 
Bifidobacterium breve 99. 
13. Probiotics in cardiovascular diseases[44, 47,48] 
Cardiovascular abnormalities and complications are one of 
the major reason of deaths in the recent some decades. 
Amongst the various reasons, the diet and food habit is one 
of the most influencing factor for the development of 
cardiovascular complications. Hence the functional foods 
gaining the great popularity and acceptance. These are the 
nutritionally enriched products that provide health benefits 
along with the basic nutritional purpose. As said earlier the 
increased number of deaths occurs due the cases of different 
form of cardiovascular diseases. As the food have direct 
impact on health it is essential controlling and examination 
of dietary pattern and food habits for the minimizing the risk 
of development of coronary heart diseases. For e.g. 
Resveratrol which are present in red wine have an 
antioxidant property and it decrease the cardiac fibrosis. In 
this condition fibroblast are over activated in heart which 
results into production of collagen. Elevated level of 
produced collagen causes stiffening of heart muscle. Due to 
stiffened muscle heart loses its efficiency of bold pumping.  
Cholesterol level in body is also directly depending upon the 
diet. The food with high fat and cholesterol content lead to 
overweight i.e. obesity. Obeys patients are at the high risk of 
cardiovascular diseases. Probiotics doesn’t have direct action 
on heart but still it reduces the incidences of cardiac 
complications. The probiotic bacteria have action on fat 
deposition mechanism hence the probiotic bacteria 
decreases the deposition of fat which lowers the risk 
cardiovascular disease. In vitro study shows that some 
strains of Lactobacillus such as Lactobacillus helvetics, 
Sacccharomyces cerevisie, Lactobacillus hekveticus CP790 
have ability to produce bioactive peptides. These peptides 
inhibit the activity of Angiotensin Converting Enzyme (ACE). 
This enzyme play major role in hypertension. Hence 
probiotics alleviate the hypertensive crises. Probiotic also 
protect heart from foodborne pathogenic microorganism 
hence provide protection against carditis. By these different 
actions probiotic can provide protection to heart from 
different risk factor. 
PROBIOTICS DELIVERY MECHANISMS 
Various approaches are used for the effective delivery of the 
probiotic bacteria to the gastrointestinal tract including 
various non-conventional product and conventional 
pharmaceutical dosage forms. Various non-conventional 
products are food based commercial products such as 
cheeses, chocolates, yogurts, creams, milk etc. Conventional 
pharmaceutical formulations include the different 
pharmaceutical dosage forms. Vishwakarma N, 
Ganeshpurkar A et.al. developed and formulated Mesalazine 
probiotics loaded pectin beads as a novel promising strategy 
for UC. The probiotics are delivered as Polysaccharide based 
hydrogel as promising probiotics drug delivery system. Some 
bacterial strains are delivered as modified emulsion based 
gel as carrier using natural gums. Mateescu MA, Calinescu C 
developed chitosan self-stabilized matrix based colon 
targeted probiotics delivery system formulation. This 
formulation maintain the viability of the probiotic bacteria 
Immunomodulation Mechanisms of Probiotics 
Activation of humoral 
immune response 
Activation of 
cellular immune 
response 
Production of anti-
influenza immunoglobulin 
G (IgG) and antirotaviral 
IgA production.  
E.g. Bifidobacterium breve 
 
 Stimulation of Helper T cells (type 1) e.g. L. casei 
 Macrophages stimulation and production of IL, TNF-
α and NO. 
 Mononuclear cells stimulation results of pathogenic 
bacteria from circulation. E.g. L. acidophilus 
 Increase kupffer cells leads to pathogenic. 
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and also protect the bacteria strain from surrounding 
condition and maintain the stability. The probiotics itself can 
be used as the carrier for the carrying the vaccines and 
immunological products. Engineered probiotics are also 
novel way to effective localization and delivery of the 
probiotics. Okonogi S, Klayraung S et.al. has developed 
probiotics containing tablets using the Lactobacillus 
fermentum 2311 as bacterial culture using polymers such as 
hydroxypropyl methyl cellulose. Chong-suchoet.al. prepared 
microcapsule for the oral delivery of probiotics expressing M 
cells homing peptide conjugate BmpB vaccine by 
encapsulating it into microcapsules by the 
microencapsulation process. Witzler J.J.P, Pinto R.A. et.al. 
developed a probiotic formulation in form of lozenges foe 
delivery of Enterococcus faecium CRL 183. Edible films are 
also used as carrier for probiotics.By such different 
approaches the probiotics bacteria are delivered in the 
various regions of gastrointestinal tract. [30, 32, 49, 50, 51, 52] 
    RECOMBINANT PROBIOTICS 
In the recent era of research and development, recombinant 
technology have gaining the significant importance in the 
biotechnological field. The probiotic are not the exception for 
recombinant technology. Recent advances of this technology 
are utilized for development of effective and safe probiotics. 
Recombinant technology involves the transfer of certain 
gene from on organism to the other organism using specific 
vector such as plasmid. Due to which the new organism have 
better and required characters and properties. Probiotics are 
used for nutrition, food and health from many years. 
Probiotics have wide range of actions and therapeutic 
application. The intensity of action, mechanism, safety and 
specificity of probiotics are differ from species to species and 
strain to strains. Novel approaches of recombinant 
technology in probiotics are used to deliver the probiotic 
molecule at targeted site of mucosal surface as targeted drug 
delivery in nutrition and health which facilitates accurate 
targeting of therapeutics. It is essential to carefully evaluate 
the probiotic strain for virulence and its sensitivity before 
considering as probiotic. Carrier microorganism used for 
recombinant probiotic must be therapeutically safe, 
especially in the cases where they are going to use in 
diseased conditions. Some probiotic strains are very 
sensitive to many factors such as heat, gastrointestinal 
acidity and oxygen and hence it become challenging process. 
It is essential that the probiotic produced by recombinant 
biotechnological process should comply with required 
criteria such as safety, high survival rate during processing, 
maintenance of viability, heat stability and acid stability. All 
such aspects should be scientifically validated. In this 
technology, expressing gene from the strain with good 
efficacy and potency are separated and such encoded gene 
are introduced in intended probiotic which having resistance 
to the most of the stress factors.[53] Recombinant probiotic- 
Subalin is the new class of probiotic which is developed by 
the recombinant biotechnological process which produces 
certain predetermined and intended therapeutic proteins. 
For the subalin development Bacillus subtilis 2335 strain are 
used. This strain having ability to synthesize of human 
interferon alpha-2 which shows marked antiviral action. This 
property of Bacillus subtilis 2335 are transformed by plasmid 
in parent culture. Parent culture shows antibacterial 
properties. By using these strains, Sorokulova et al. in 1997 
developed new probiotic having both antiviral and 
antibacterial properties. Subalin is free from any kind of 
adverse effect. When subalin was studied in combination 
with neoplastic drug cyclophosphamide to assess the 
effectiveness in antitumor treatment, it was observed that 
the therapy with subalin showed higher inhibition of growth 
of tumor and its spreading as compared to the alone 
cyclophosphamide. Subalin inhibit growth of tumor due to 
the ability of recombinant subalin to induce the production 
of endogenous interferon. Lactobacillus lactis strain 
producing iterleukin-10(IL-10) was studied in phase 1 
clinical trial on patients with chrohn’s disease. Hence the 
probiotics developed by the recombinant biotechnological 
process are more superior in every aspects such as potency, 
spectrum of action, specificity and safety. [35] 
SAFETY OF PROBIOTICS 
Probiotics have been used for several years and are regarded 
as safe. “The origin of many probiotics is from humans which 
have a long back history of safety along with the use 
probiotics.” This statement is supported for the safety issue 
of probiotics from the human origin. It has long record of 
safety. In ambulatory care, almost no side effect has been 
reported. In 2011, Agency for Healthcare Research and 
Quality released a report in which, it is stated that, however 
the existing clinical trials for probiotics reveal no significant 
evidence of increased risk, and “the current literatures are 
not equipped to answer the question on the safety of 
probiotics in interventions studies with confidence.” 
Due to deficiency of industry standardization and safety 
issues have troubled the probiotics use with various views 
against probiotics despite the health benefits. The 
epidemiological studies in adult shows low rate of systemic 
infection between 0.05 to 0.40 %. In pregnancy and in 
infancy they are considered safe. Mainly side effects are 
reported primarily in those people with underlying medical 
condition.[13,54] The US Food and Drug Administration 
(USFDA) designation Generally Recognized as Safe (GRAS)| 
has been applied to probiotics microbes viz; yeast, 
lactobacilli, bifidobacterium, lactococcia etc. Enterobacteria 
and enterococci not classified under GRAS. When they are 
added to food, although some systemic safety studies has 
been carried especially in vulnerable peoples. [55] The 
standardized and validated safety assessment techniques for 
novel probiotics and especially genetically modified 
probiotics needed to be established. Main observed side 
effects of probiotic strains were fungemia, sepsis, and GI 
ischemia. These adverse events are observed in patients with 
critically ill conditions in ICU or patients with immune- 
compromised complexity. 
As per joint FAO/WHO expert committee guidelines, (2002 
a.b.) safety of probiotics strain can evaluated by a set of tests 
viz; antibiotic resistance pattern, eventual side effects, 
definite metabolic activities, potential virulence factor. There 
are some factors related to the safety of probiotics for their 
use as per the safety assessment guidelines as FAO:- 
1) Description of use of probiotics (dose, format and 
stability). 
2) Validation that the product is manufactured under 
Good Manufacturing Practices specific for the product 
category. 
3) Extend of probiotics involved in adverse events. 
4) Physiological and genetic capacity determination for 
toxic activities. 
5) Genetic stability of probiotics. 
6) Determining the pattern of antibiotic resistance. 
7) Physiological and genetic capacity determination for 
pathogenic/ opportunistic pathogenic activities. 
8) Evaluation of safety of probiotics by the regulatory 
authority or a panel of expert qualified in the field for 
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intended use, depending on the product category and 
requirements. 
9) Assessment of metabolic activities. 
10) Assessment of adverse effects during study. 
For the assessment of safety of probiotics, clinical trials are 
necessary. But they are very expensive and may cause 
adverse effects to the human volunteers in clinical trials. 
Therefore, to avoid such harmful effects, in vitro study 
performed on the probiotics to determine possible 
mechanism of action. 
Criteria for selection of strain in human study are- 
1) Absence of resistance to clinical/ veterinary antibiotics. 
2) Non-appearance of virulence factors. 
The safety of probiotics documented for infants which is 
referred to as innocuous substance. There are different 
safety profiles for the different strains of probiotics. Safety of 
probiotics classified on the basis of their strain-by-strain 
basis; dose and interactions with other bacterial strains and 
pathological conditions. [15, 56, 57, 58, 59] 
CONCLUSION AND CURRENT ASPECTS 
Probiotics is one of the important field in research and 
technology. It is an emerging subject for researchers. Many 
studies carried out on probiotics in food reduces the risks of 
diseases to somewhat manner. Now a day’s use of probiotics 
increased significantly because of its successful 
administration through different routes with minimum side 
effects. Many of the probiotic species sold commercially in 
large amount to overcome symptoms of disorders. [9, 35, 61] 
Now days, studies are undergoing on the probiotics to 
discover the emerging applications of probiotics. Current 
research is going to discover the proper mechanism of action 
of probiotics in specific disease or disorder. In many causes, 
prebiotics showed their action but the mechanism remains 
unclear. Currently, many works going on the formulation 
aspects of probiotics for its proper administration. Different 
formulations of probiotics available commercially viz; 
microcapsules, nanoemulsion, nanosuspension. [10] Many 3D 
printed tablets also available for better administration of 
probiotics. Many works going on the 3D printing of 
probiotics. Probiotics is one of the best tool to cure disease 
and disorders from new born to adults. [4, 6] 
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